Bioasis Technologies Inc. V.BTI

panobinostat, lomustine, xB3-bevacizumab

[prophetoffactz]

Midatech's lead drug currently in clinical trials is panobinostat and seeks to bypass the blood-brain barrier directly into the brain tumor. The current clinical trial will study panobinostat alone and in combination with lomustine. BTI has reseached xB3 with bevacizumab for this same tumor. Could these drugs together, with Midech's and BTI's delivery technology, solve the problems of previous trials?


"There are several potential reasons for the lack of activity with this combination. The dose of panobinostat used in this study was the maximum tolerated dose determined in our preliminary phase I study.19 Even though this dose is being explored in hematologic malignancies, it may be too low to achieve adequate tumor concentrations in the brain. This issue is compounded by the limited penetration of panobinostat across the blood-tumor barrier, a problem that is further exacerbated by combining it with bevacizumab, which reduces vascular permeability. In contrast, lomustine, which does penetrate the blood-tumor barrier, was successfully combined with bevacizumab for treatment of recurrent GBM.27 This difference underscores the need to combine bevacizumab with agents that have good blood-tumor barrier penetration. In addition, there are no preclinical data exploring the activity of the combination of panobinostat and bevacizumab in GBM models."

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma | Neuro-Oncology | Oxford Academic (oup.com)

[prophetoffactz]

BTI's presentation states the glioblastoma market is US$2.4 billion and growing a 8.8% per year until 2028. This is a big problem to be working on as a lead asset and if safety risk is largely addressed that may only leave efficacy as the primary risk. Can Biodexa solve this billion dollar problem?

[JDavenport]

Yes, there is reason to believe that Biodexa will survive. They will have a compelling pipeline. But they will need to raise a lot of money for clinical and operational purposes. They can raise money by selling the xB3 platform, which I think may be initial the plan. Biodexa would keep the xBe assets and partnerships existent at the time of this deal's completetion. The buyers of the xB3

[craighenry]

"A billion shares outstanding " hey JD? SMH.... you  cant make this up...... My god.

[JDavenport]

I confess, craig, I lied. It's only 909,652,073 shares. 909,652,073 isn't even close to a billion.  jd

[craighenry]

Absolutely clueless JD.   Lets see: MTP currently has 3.94 Million shares outstanding  plus approx 76 million issued for the Bioasis merger (footnote below)  To me that is approx. 79.4 million shares outstanding.  No wonder DR dropped your butt.  Absolute incompetence.   She saw that a mile a way.  John, there is a reason GD is still employed by

[craighenry]

I left out the warrant structure because because there are a lot of factors at play. But Im sure you understand.   LoL! Midatech is also pleased to announce a two-stage fundraise of approximately US$10.0 million (c.£8.2 million) gross proceeds, comprising of: (i) gross proceeds of approximately US$0.4 (c.£0.3 million) raised pursuant to the Registered Direct Offering in

[JDavenport]

Yes, craig, I mean, no, craig, the documents do not lie. I take them completely at their word. jd

[prophetoffactz]

"Yes, there is reason to believe that Biodexa will survive. They will have a compelling pipeline." xB3 has never been in a stronger position.   With Biodexa a multi-asset clinical stage company able to take assets into clinical trials on its own, if xB3 is validated by J&J in the next approximately 30 business days through the multi-product option exercise this company can look

[JDavenport]

poofster says, "xB3 has never been in a stronger position." That's true, I agree.  And Bioasis shareholders have never been in a weaker position. jd

[prophetoffactz]

So now instead of 24,000% upside to Denali they have 1/10 of that or 2,400%. But the clinical assets BTI is being merged with may be substantially undervalued themselves and given the revenue generating potential there is a chance to limit dilution. Also, given the clinical trial infrastrucutre BTI will now have it is now positioned to advance xB3 assets themselves and enter more substantial

[JDavenport]

Oh, yes, craig, That is exactly what it looks like. You are correct. No argument. jd

[prophetoffactz]

Given BTI's share price of C$.15 with virtually no volume, the debt, and the state of the markets with many biotech stocks trading below cash if BTI tried to raise US$10 million with warrants all on its own given its history how much dilution would it suffer? It could still be 2 years from a clinical trial meaning even more dilution. It wasn't a good situation. 

[JDavenport]

Yo, poof, a doubling, or a tripling of the float, to do a financing with the resulting half or third of ownership of Bioasis and the xB3 platform that shareholders now completely own would be worse that a declining 9.6% stake in Biodexa, likely without the xB3 platform?. Is that it?  I won't be voting. You and the other shareholders will.be voting for it. Don't worry. The deal will

[prophetoffactz]

Conclusion: This study shows that lomustine and bevacizumab can effectively increase OS, PFS, and 6-month PFS in patients with GBM. The encouraging results of the lomustine and bevacizumab combination therapy for GBM should be studied in more clinical trials in the future. Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis - PubMed (nih.gov)